Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride

EU orphan designation number: EU/3/07/459   
Active ingredient: 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride
Indication: Treatment of narcolepsy
Sponsor: Bioprojet Pharma
9 rue Rameau, F-75002 Paris, France
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Wakix on 31/03/2016 with the number EU/1/15/1068

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/07/2007 Orphan designation EMEA/OD/087/06 (2007)3432 of 10/07/2007
26/11/2015 Change of name and/or address of sponsor